Dear Mr. Sawhney:

This NDA provides for the use of Lamivudine and Zidovudine Tablets, 30 mg/60 mg in combination with other antiretrovirals for the treatment of HIV-1 infection.

This NDA was reviewed under the President’s Emergency Plan for AIDS Relief (PEPFAR).

We completed our review of this application. It is **tentatively approved** under 21 CFR 314.105 for use as recommended in the agreed-upon labeling (refer to the enclosed text for the package insert, immediate container, and bulk pack labels). Also refer to your original submission dated January 21, 2008, for the immediate container and bulk pack labels and to the agreed-upon labeling emailed on July 9, 2009, for the package insert. Based on the data provided, the expiration dating period is 24 months for Lamivudine and Zidovudine Tablets, 30 mg/60 mg in HDPE containers of 60 and 1000 tablets and PVC/PVdC with aluminum foil blister packs of 10 when stored at 20º-25ºC (68º to 77ºF). LDPE bags of 10,000 for bulk shipment (for repacking within 6 months) are also included in this action.

The tentative approval is predicated upon information available to the Agency at this time (i.e., information in your application and the status of current good manufacturing practices of the facilities used in manufacturing and testing of the drug products) and is, therefore, subject to change on the basis of any new information that may come to our attention.
The listed reference drug products upon which you base your application are subject to a period of patent protection and therefore, final approval of your application under section 505(b) may not be made effective until the period has expired. If you have questions as to when this date will be, please contact the Agency at the information provided below.

At least 180 days prior to the expiration of patent protection or when requested, please submit a “MINOR AMENDMENT – FINAL APPROVAL REQUESTED” as an amendment to this application identifying changes, if any, in the conditions under which your product was tentatively approved. This information should include updated labeling, chemistry, manufacturing and control data, and a safety update. This amendment should include draft final printed labels and labeling which comply with all United States regulations (uniqueness of drug product appearance per 21 CFR 206; child-resistant packaging per 16 CFR 1700, etc.). This amendment should be submitted even if none of these changes were made. This amendment should be designated clearly in your cover letter as a “MINOR AMENDMENT – FINAL APPROVAL REQUESTED.”

Failure to submit this amendment will prompt a review of this application that may result in rescission of the tentative approval status of your application, or may result in a delay in the issuance of the final approval letter.

Any significant change in the conditions outlined in this NDA requires our review before final approval may be granted.

We remind you that you are expected to comply with the reporting requirements provided in 21 CFR 314.80 and 314.81. If the drug product is to be mass distributed in developing countries, a system of collecting and reporting adverse drug reactions by the distributor would be desirable (e.g., through governmental or nongovernmental agencies distributing the products).

We remind you that, should you intend to market this product in the United States after the period of patent protection, you are required to join the antiretroviral pregnancy registry at that time and make the appropriate labeling change that references the existence of the pregnancy registry. In addition, an updated package insert (PI) must be submitted under the Structured Product Labeling requirements (http://www.fda.gov/oc/datacouncil/spl.html) as defined by the Physician’s Labeling Rule [21 CFR 201.56, 201.57].

Before we issue a final approval letter, this NDA is not deemed approved. If you believe that there are grounds for issuing the final approval letter before the period of patent protection has expired, you should amend your application accordingly.

This product may be considered misbranded under the Federal Food, Drug, and Cosmetic Act if it is marketed in the United States before final approval.

If you have any questions, please contact Monica Zeballos, Pharm.D., Senior Program Consultant, at (301) 796-0669 or by email at monica.zeballos@fda.hhs.gov.
Sincerely yours,

{See appended electronic signature page}

Jeffrey Murray, M.D., M.P.H.
Deputy Director
Division of Antiviral Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

Attachments: Draft PI, immediate container and bulk pack labels

Emailed CC: Blessy Johns, U.S. Agent for Aurobindo
2400 Route 130
North Dayton, NJ 08810
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Jeffrey Murray